Brainstorm Cell Therapeutics (NASDAQ:BCLI) Issues Quarterly Earnings Results

Brainstorm Cell Therapeutics (NASDAQ:BCLI) issued its earnings results on Thursday. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.12, MarketWatch Earnings reports.

BCLI stock opened at $15.29 on Friday. The company’s 50 day simple moving average is $14.59 and its 200-day simple moving average is $10.66. The firm has a market capitalization of $482.68 million, a PE ratio of -13.18 and a beta of 0.83. Brainstorm Cell Therapeutics has a 12 month low of $3.58 and a 12 month high of $17.95.

Several research analysts have weighed in on BCLI shares. BidaskClub upgraded shares of Brainstorm Cell Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 30th. Maxim Group upped their target price on shares of Brainstorm Cell Therapeutics from $9.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Featured Article: CBOE Russell 2000® Volatility Index

Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.